In 1994 was created Sanofi-Genzyme BioVentures, which is appeared as VC. The fund was located in North America if to be more exact in United States. Sanofi-Genzyme BioVentures appeared to be a CVC structure as part of the corporation. The leading representative office of defined VC is situated in the Cambridge.
The average startup value when the investment from Sanofi-Genzyme BioVentures is 100-500 millions dollars. The increased amount of exits for fund were in 2017. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund. Opposing the other organizations, this Sanofi-Genzyme BioVentures works on 3 percentage points more the average amount of lead investments.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Sanofi-Genzyme BioVentures, startups are often financed by New Enterprise Associates, GE Ventures, U.S. Venture Partners (USVP). The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Novartis Venture Fund, Atlas Venture. In the next rounds fund is usually obtained by Wellington Management, Rock Springs Capital, RA Capital Management.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Omada Health, Expansion Therapeutics, Evidation Health.
The overall number of key employees were 4.
Fund Name | Location |
7 Industries | Netherlands, Noord-Holland, North Holland |
Aries Capital Partners | Salt Lake City, United States, Utah |
Camel Group | China, Hubei, Xiangyang |
Cypherpunk Holdings Inc. | Canada, Ontario, Toronto |
ETH Zurich Foundation | Switzerland, Zürich, Zurich |
Orchid India | - |
Shooting Star | - |
Silversmith Capital Partners | Boston, Massachusetts, United States |
Wasatch Funds | Sandy, United States, Utah |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
NextPoint Therapeutics | $42M | 14 Feb 2024 | Cambridge, Massachusetts, United States | ||
Sudo Biosciences | $30M | 13 Feb 2024 | Menlo Park, California, United States | ||
Sudo Biosciences | $116M | 20 Dec 2023 | Menlo Park, California, United States | ||
Eligo Bioscience | $32M | 05 Dec 2023 | Paris, Ile-de-France, France | ||
T-Therapeutics | $65M | 15 Nov 2023 | Cambridge, Cambridgeshire, United Kingdom | ||
ReCode Therapeutics | $50M | 19 Sep 2023 | Dallas, Texas, United States | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Abcuro | $155M | 17 Aug 2023 | Newton, Massachusetts, United States | ||
Tisento Therapeutics | $81M | 31 Jul 2023 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
NextPoint Therapeutics | $42M | 14 Feb 2024 | Cambridge, Massachusetts, United States | ||
Sudo Biosciences | $30M | 13 Feb 2024 | Menlo Park, California, United States | ||
Sudo Biosciences | $116M | 20 Dec 2023 | Menlo Park, California, United States | ||
Eligo Bioscience | $32M | 05 Dec 2023 | Paris, Ile-de-France, France | ||
T-Therapeutics | $65M | 15 Nov 2023 | Cambridge, Cambridgeshire, United Kingdom | ||
ReCode Therapeutics | $50M | 19 Sep 2023 | Dallas, Texas, United States | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Abcuro | $155M | 17 Aug 2023 | Newton, Massachusetts, United States | ||
Tisento Therapeutics | $81M | 31 Jul 2023 | Cambridge, Massachusetts, United States |